Consumers are treating fish oil capsules and fortified foods less like a luxury and more like routine preventive care, and manufacturers are racing to keep pace. According to Polaris Market Research, the North America Omega 3 Market was valued at USD 826.27 million in 2023 and is projected to reach USD 1,567.13 million by 2032, growing at a CAGR of 7.5%.

The Shift: What's Actually Changing in Omega 3 Demand

The change is behavioral as much as scientific. Chronic conditions such as cardiovascular disorders, arthritis and cognitive decline are pushing people toward proactive health measures, and EPA and DHA are among the most studied nutrients for heart and brain health. For context, the CDC reported roughly 695,000 heart disease deaths in the United States in 2021. Rising costs reinforce the trend: according to the Centers for Medicare & Medicaid Services, U.S. national health expenditure grew 4.1% to USD 4.5 trillion in 2022, nudging households to see supplements and functional foods as affordable prevention. That is the engine behind current industry trends and sustained market growth. Supportive regulatory frameworks and ongoing product innovation add further momentum.

North America Omega 3 Market by the Numbers

With the market estimated at USD 875.65 million in 2024, the trajectory looks like this:

• 2023 Market Size: USD 826.27 million
• 2032 Projected Size: USD 1,567.13 million
• CAGR (2024–2032): 7.5%

👉 Want the full data behind this shift? Get a Free Sample Report → 

https://www.polarismarketresearch.com/industry-analysis/north-america-omega-3-market 

Growth Drivers, Key Players and Market Segments to Watch

The expansion is being driven by rising healthcare expenditure and growing consumer awareness — Natac's March 2025 launch of Omega-3 Star, a fish oil solution for food, nutraceutical and pet nutrition, shows the innovation pipeline at work — with key players including Aker BioMarine, BASF SE, Croda International, and DSM-Firmenich shaping the competitive landscape across segments such as By Type (DHA, ALA, EPA), By Source (plant-based, marine-based), By Application, and By Country. As healthcare costs take a bigger share of household budgets, people look for convenient ways to manage their health before problems escalate, and omega-3s have been studied for cardiovascular support, cognitive function and inflammation reduction, which is why they increasingly sit inside a preventive routine.

Segment and Competitive Highlights

Marine-based sources held the largest share in 2023, helped by the region's abundant fish species, mature supply chains and the high EPA and DHA concentrations that plant sources such as flaxseed or algal oil struggle to match. By application, pharmaceuticals is expected to record the fastest CAGR as prescription omega-3 products gain traction for conditions such as elevated triglycerides. Buyers benchmarking top companies will also find GC Rieber, Omega Protein, Corbion, Nuseed Global and Cargill in the report. Marine-based products come as softgel capsules, liquid oils and fortified foods, a breadth that suits diverse dietary needs, while functional food and beverages, infant formula, dietary supplements and animal feed and pet food complete the application picture.

Challenges That Could Slow Growth

Alternatives are the main headwind. Concerns about sustainability, contaminants such as heavy metals, and the needs of vegetarian and vegan consumers are steering some buyers toward algae-based omega-3, which offers comparable benefits without the fish. As awareness of these alternatives grows, demand for fish oil-derived products could soften, so suppliers with both marine and plant-based portfolios may be better positioned.

The United States Leads Today, but Pharma-Grade Omega 3 Is Catching Up Fast

The United States accounted for more than 38% of the total in 2023, a lead built on high disposable incomes, a strong wellness culture and a healthcare system in which physicians, nutritionists and pharmacists routinely recommend omega-3 products. The pharmaceutical segment, however, is projected to post the highest CAGR through 2032 as clinical research keeps supporting EPA and DHA formulations and drug developers invest in optimized prescription versions. Canada rounds out the country coverage in the report.

What This Means for Teams Tracking the Omega 3 Market Forecast 2032

For ingredient suppliers, supplement brands and investors researching the North America Omega 3 market forecast 2032, the underlying report breaks down company positioning, segment-level forecasts, and regional opportunity through 2032 — useful context for any sourcing, partnership, or investment conversation happening right now. The split between marine and plant-based sources, and between dietary supplements and pharmaceutical-grade products, will shape where margins and growth concentrate.

The Road Ahead

The next few years are likely to reward companies that balance supply security with sustainability. Polaris anticipates strategic collaborations, partnerships, mergers and acquisitions among leading players, which should drive consolidation and product innovation. As algae-based options mature and prescription formulations expand, an industry that began with a simple health habit is becoming a broader ingredients-and-therapeutics business. With consumers continuing to prioritize health and wellness, demand for omega-3 fortified products is anticipated to remain robust, creating opportunities for manufacturers and retailers.

More Trending Latest Reports By Polaris Market Research:

mens-jewelry-market

offshore-support-vessel-market

car-t-cell-therapy-market

top-maleic-anhydride-manufacturers-and-key-insights-2024

top-10-electric-bike-sharing-services-companies-in-2025:-future-of-e-bikes-sharing

polyvinyl-chloride-pvc-market

cannabidiol-market

smart-home-energy-monitoring-devices-market

dental-loupe-market